The EMI Scheme is supported by: the Cambridge University Hospitals, NIHR Cambridge Biomedical Research Centre and Industry Partners. Prospective Pharmaceutical Industry companies who are interested in joining in this strategic scheme should contact Prof Ian Wilkinson or Dr Nicola White in the first instance.
Current EMI Industry Partners include AstraZeneca/MedImmune and GlaxoSmithKline:
About AstraZeneca and MedImmune
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory & Autoimmunity, Cardiovascular & Metabolic Disease and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com.
AstraZeneca is constructing a new R&D centre and corporate headquarters at 1 Francis Crick Avenue, Cambridge Biomedical Campus; which will bring scientists from across both organisations together in one place in the UK.
MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com
AstraZeneca and MedImmune aim to support projects aligned to their main focus areas which are also of mutual interest to the EMI Scheme and academic partners.
GSK is a science-led, global healthcare company, committed to widening access to their products, so more people can benefit, no matter where they live or what they can afford. They employ approximately 16,000 people across 18 sites in the UK. In order to advance the training of bioscience skills and knowledge of the next generation of scientists, GSK and its Affiliates provides funding to the academic research base by supporting collaborations with academia for collaborative post-graduate research doctoral studentships and in this instance aims to support the University of Cambridge to train academic physician scientists in Experimental Medicine.